SCYX vs. GANX, IMMX, HOOK, APLM, CLNN, ANEB, YS, RLYB, LPTX, and DERM
Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Gain Therapeutics (GANX), Immix Biopharma (IMMX), Hookipa Pharma (HOOK), Apollomics (APLM), Clene (CLNN), Anebulo Pharmaceuticals (ANEB), YS Biopharma (YS), Rallybio (RLYB), Leap Therapeutics (LPTX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical preparations" industry.
SCYNEXIS (NASDAQ:SCYX) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.
SCYNEXIS has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.
SCYNEXIS has a net margin of 53.14% compared to Gain Therapeutics' net margin of 0.00%. SCYNEXIS's return on equity of 238.09% beat Gain Therapeutics' return on equity.
SCYNEXIS received 486 more outperform votes than Gain Therapeutics when rated by MarketBeat users. Likewise, 70.19% of users gave SCYNEXIS an outperform vote while only 56.25% of users gave Gain Therapeutics an outperform vote.
Gain Therapeutics has lower revenue, but higher earnings than SCYNEXIS. Gain Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
In the previous week, SCYNEXIS had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 2 mentions for SCYNEXIS and 1 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.96 beat SCYNEXIS's score of 0.83 indicating that Gain Therapeutics is being referred to more favorably in the news media.
SCYNEXIS presently has a consensus target price of $12.25, indicating a potential upside of 750.69%. Gain Therapeutics has a consensus target price of $8.33, indicating a potential upside of 91.13%. Given SCYNEXIS's higher probable upside, equities analysts plainly believe SCYNEXIS is more favorable than Gain Therapeutics.
49.9% of SCYNEXIS shares are owned by institutional investors. Comparatively, 10.0% of Gain Therapeutics shares are owned by institutional investors. 4.4% of SCYNEXIS shares are owned by insiders. Comparatively, 11.0% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
SCYNEXIS beats Gain Therapeutics on 12 of the 16 factors compared between the two stocks.
Get SCYNEXIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
SCYNEXIS Competitors List
Related Companies and Tools